Core Viewpoint - Yueyang Xingchang's stock closed at 16.39 yuan on August 15, with a PE ratio of 109.90, marking a new low in 16 days, and a total market capitalization of 6.059 billion yuan [1] Company Summary - Yueyang Xingchang specializes in the development, production, and sales of petrochemical products, including chemical new materials, energy conservation and environmental protection, and retail of refined oil [1] - The company's main products include methyl tert-butyl ether, liquefied petroleum gas, propylene, industrial isooctane, ortho-cresol, calcined petroleum coke, and special polypropylene [1] - For Q1 2025, the company reported operating revenue of 1.063 billion yuan, a year-on-year increase of 27.85%, and a net profit of 13.6081 million yuan, a year-on-year decrease of 37.00%, with a gross profit margin of 18.85% [1] Industry Summary - The average PE ratio for the petroleum industry is 12.81, with a median of 28.49, placing Yueyang Xingchang at the 18th position in the industry ranking [2] - The company experienced a net inflow of 5.1876 million yuan in main funds on August 15, but had a total outflow of 25.0874 million yuan over the past five days [1]

8月15日，海德股份今日收盘6.65元，上涨1.22%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到67.04倍，总市值129.98亿元。 从行业市盈率排名来看，公司所处的多元金融行业市盈率平均50.44倍，行业中值30.65倍，海德股份排 名第16位。 资金流向方面，8月15日，海德股份主力资金净流出26.63万元，近5日总体呈流出状态，5日共流出 2268.58万元。 海南海德资本管理股份有限公司的主营业务是科技清收个贷不良服务业务、机构困境资管业务、优质资 产管理业务。公司的主要产品是资产管理、金融科技服务。 最新一期业绩显示，2025年一季报，公司实现营业收入2.21亿元，同比-36.02%；净利润9704.45万元， 同比-58.40%，销售毛利率98.91%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)12海德股份67.0439.372.44129.98亿行业平均 50.4442.691.86234.24亿行业中值30.6526.271.83191.77亿1江苏金租11.2711.501.36338.27亿2陕国投 A13.6914.091.05191.77亿3越秀资本 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jiuzhou Yiguai Environmental Technology Co., Ltd, which has a high PE ratio compared to its industry peers [1][2] - Jiuzhou Yiguai's current stock price is 13.13 yuan, with a PE ratio of 167.07, significantly higher than the industry average of 58.87 and the median of 33.55 [1][2] - The company's total market capitalization is 1.973 billion yuan, ranking 107th in the environmental industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, only two institutions hold shares in Jiuzhou Yiguai, with a total of 144,000 shares valued at 0.02 million yuan [1] - The company reported a revenue of 26.0584 million yuan for the first quarter of 2025, reflecting a year-on-year decrease of 44.47%, and a net loss of approximately 6.0249 million yuan, with a gross profit margin of 15.59% [1] - Jiuzhou Yiguai specializes in research and development, manufacturing, engineering design, marketing, testing consulting, and operational management services related to rail transit vibration and noise reduction technology [1]

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，安杰思排名 第49位。 截至2025年半年报，共有10家机构持仓安杰思，其中其他5家、基金4家、券商1家，合计持股数1763.84 万股，持股市值11.43亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。公司获得多项政府荣誉，主要包括"浙江省 出口名牌"称号，"临平区人民政府质量奖"等奖项。 8月14日，安杰思今日收盘80.7元，下跌5.36%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到22.16倍，总市值65.35亿元。 最新一期业绩显示，2025年半年报，公司实现营业收入3.02亿元，同比14.56%；净利润1.26亿元，同比 1.26%，销售毛利率70.21%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安杰思22.1622.272.6965.35亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.181 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry, indicating a decline in revenue and profit in the latest quarterly report [1][2] - As of August 14, Haohai's closing stock price was 54.63 yuan, with a PE ratio of 30.75 times, and a total market capitalization of 12.706 billion yuan [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Haohai at the 61st rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Haohai achieved an operating revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.3121 million yuan, down 7.41% year-on-year, with a gross profit margin of 69.52% [1] - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

8月14日，佰仁医疗今日收盘119.24元，下跌2.09%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到96.33倍，总市值164.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，佰仁医疗排 名第104位。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13佰仁医疗96.33112.2512.76164.25亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18 ...

截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 8月14日，振德医疗今日收盘23.22元，下跌1.32%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到17.04倍，总市值61.87亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，振德医疗排 名第36位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗17.0416.061.0861.87亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿6奥美医疗 17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱18.2218.241.5139.27亿9奥泰生物 18.4419.441.4958.81亿10维力医疗18.4 ...

Core Viewpoint - The company, Lifetech Scientific Corporation, is currently facing a decline in stock price and performance metrics, with a PE ratio lower than the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Lifetech Scientific Corporation's stock closed at 13.07 yuan, down 2.83%, with a rolling PE ratio of 40.15 times and a total market capitalization of 7.576 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, sales, and service of medical electronic devices and in vitro diagnostic products [1]. - Key products include critical care monitoring solutions, bedside monitoring solutions, smart vital sign management solutions, various ECG and ultrasound systems, and molecular diagnostic products [1]. Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit was 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [1]. - The sales gross margin stood at 58.34% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Lifetech Scientific Corporation at the 78th rank within the industry [1][2]. - The company is held by four institutions, all of which are funds, with a total holding of 55,200 shares valued at 0.01 million yuan [1].

序号股票简称PE(TTM)PE(静)市净率总市值(元)13乐普医疗223.93130.232.09321.58亿行业平均 55.7651.784.92117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18.2218.241.5139.27亿9奥泰生物18.4419.441.4958.81亿10维力医疗18.4719.732.3243.29亿11鱼跃医疗 20.1919.802.73357.58亿12安图生物20.6219.682.65235.08亿 来源：金融界 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产 品是医疗器械、药品、医疗服务及健康管理。 最新一期业绩显示，2025年一季报， ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Huayang International, indicating a decline in stock price and a relatively low PE ratio compared to the industry average [1][2] - As of August 14, Huayang International's stock closed at 14.09 yuan, down 2.42%, with a rolling PE ratio of 22.16 times and a total market capitalization of 2.762 billion yuan [1] - The average PE ratio for the engineering consulting service industry is 65.28 times, with a median of 39.48 times, positioning Huayang International at 26th place within the industry [1][2] Group 2 - The company reported a revenue of 264 million yuan for Q1 2025, reflecting a year-on-year increase of 15.36%, while net profit was 2.4757 million yuan, showing a year-on-year decrease of 20.22% [1] - The gross profit margin for the company stands at 19.48% [1] - Huayang International specializes in architectural design and consulting, building technology innovation, and extending the industrial chain, and is recognized as a national high-tech enterprise [1]